4.7 Article

Rates, predictors, and consequences of remission from chronic migraine to episodic migraine

期刊

NEUROLOGY
卷 76, 期 8, 页码 711-718

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31820d8af2

关键词

-

资金

  1. Ortho-McNeil Neurologics, Inc., Titusville, NJ
  2. Allergan, Inc., Irvine, CA
  3. Bayer Schering Pharma
  4. Merck Serono
  5. GlaxoSmithKline
  6. Endo Pharmaceuticals
  7. Kowa Pharmaceuticals America, Inc.
  8. Allergan, Inc.
  9. Neuralieve Inc.
  10. Ortho-McNeil-Janssen Pharmaceuticals, Inc.
  11. American Headache Society
  12. Diamond Headache Center
  13. National Headache Foundation
  14. Migraine Research Foundation
  15. NIH

向作者/读者索取更多资源

Objectives: This study has 3 objectives: 1) to estimate remission rates in a population-based sample of subjects with chronic migraine (CM); 2) to identify potential predictors of CM remission; and 3) to assess the influence of CM remission on headache-related disability. Methods: The American Migraine Prevalence and Prevention study is a prospective, population-based, mailed questionnaire survey, which included questions regarding headache frequency, symptomatology, demographics, comorbidities, health care utilization, and headache-related disability. Three years of longitudinal data were analyzed to determine rates of CM remission and assess predictors of remission using logistical regression models. The consequence of remission was measured by changes in disability, as measured by the Migraine Disability Assessment, over time. Results: A total of 383 respondents had CM in 2005 and follow-up data in 2006 and 2007. Over 2 years, among those with CM at baseline, approximately 34%(n = 130) had persistent CM while 26% (n = 100) had remitted CM. In our final multivariate model, predictors of remission included baseline headache frequency (15-19 vs 25-31 headache days/month; odds ratio [OR] 0.29; 95% confidence interval [CI] 0.11 to 0.75) and absence of allodynia (OR 0.45; 95% CI 0.23 to 0.89). Preventive medication use was associated with lower remission rate (OR 0.41; 95% CI 0.23 to 0.75), but this effect lost significance when headache frequency was included. Over 2 years, those with persistent CM demonstrated increased disability while those with remitted CM demonstrated decreased disability. Conclusions: These findings have clinical practice implications, as it is important to consider that remission rates are variable. However, the benefit of remission goes beyond symptom reduction and may translate to marked decreases in headache-related disability. Neurology (R) 2011; 76:711-718

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据